Modified HScore Predicts Increased Length of Stay but not Mortality in ICU Patients with COVID-19- A Retrospective Cohort Study

Gill Jaskirat K,Bhutta Adnan T,Anders Megan G,Gibbons Miranda,Tabatabai Ali,Scalea Thomas,Peter Rock

doi:10.23937/2474-3674/1510133

Abstract

Hemophagocytic Lymphohistiocytosis (HLH) is an acute and rapidly progressive systemic inflammatory disorder that can be classified into primary HLH (pHLH), which is a pediatric disease, and secondary HLH (sHLH), which can be associated with infection, malignancy, systemic diseases or drugs.

Highlights

Severe COVID-19 disease is associated with a rapidly progressive systemic inflammatory response similar to that seen in secondary Hemophagocytic Lymphohistiocytosis
Hemophagocytic Lymphohistiocytosis (HLH) is an acute and rapidly progressive systemic inflammatory disorder that can be classified into primary HLH, which is a pediatric disease, and secondary HLH, which can be associated with infection, malignancy, systemic diseases or drugs [1]
We investigated whether modified HScore can be used within the first 24 hours of admission to the ICU to predict morbidity and mortality in critically ill adults with COVID-19

Summary

Introduction

Severe COVID-19 disease is associated with a rapidly progressive systemic inflammatory response similar to that seen in secondary Hemophagocytic Lymphohistiocytosis (sHLH). The HScore is a scoring system used to help diagnose the presence of sHLH. We investigated whether modified HScore (mHS) can be used within the first 24 hours of admission to the ICU to predict morbidity and mortality in critically ill adults with COVID-19. Accepted: January 10, 2022: Published: January 12, 2022. Gill et al Int J Crit Care Emerg Med 2022, 8:133 Page 1 of 6

Methods

Results

Discussion

Conclusion